Gordon Ramsay didn’t hold back when speaking out on whether he would alter his restaurants’ menus to cater to diners who are taking popular weight

Biomolecules, Vol. 15, Pages 1574: Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure Biomolecules

Genes, Vol. 16, Pages 1352: GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways Genes doi: 10.3390/genes16111352 Authors: Daniela

ResMed Inc (ASX: RMD) shares are marching higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) sleep disorder treatment company closed on Friday trading for

Scientists Say They’ve Figured Out a Way to Reprogram the Pancreas to Produce GLP-1s Without Ozempic  Futurism The race is on to turn your body into

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could soon

Key Points Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early Alzheimer’s drug, Kisunla, has blockbuster

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could

Scientists say they’ve come up with a way for the body to produce its own store of glucagon-like peptide-1 (GLP-1). GLP-1 is the naturally produced

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded studies raise concerns. Three new reviews from Cochrane

Some semaglutide users experience benefits beyond weight loss. Are you one of them?

Key Points Viking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug. The phase 1

Novo Nordisk selloff an opportunity if markets slump Novo Nordisk A/S Sponsored ADR Class B BATS:NVO Blueberry Markets are stretched. Tech and AI have run

As some of you may know there has been a bidding war between Pfizer and Novo Nordisk for the acquisition of Metsera. The prices of

To quote a sage There’s no such thing as a bad product, only a bad price Pfizer’s previous acqusition was Seagen on Dec 14 2023

(MedPage Today) — ATLANTA — Women who had been taking GLP-1 receptor agonist medications prior to becoming pregnant had a lower risk of gestational diabetes

(MedPage Today) — NEW ORLEANS — An investigational triple-receptor agonist made some headway in patients with severe hypertriglyceridemia, a phase II study showed. One Chinese

Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk.

A growing number of GLP-1 users are ‘microdosing’ – they say small amounts of the drug have helped reduce symptoms of various health conditions, without

Key Points Eli Lilly has plenty of medium-term catalysts that should power a strong performance through 2030. Berkshire Hathaway, by contrast, is facing some headwinds

While this coincides with an uptick in GLP-1 drug use, some experts told Newsweek they don’t think they are having a major impact.

Protein seems to be everywhere these days, with brands from Starbucks to Pepsi jumping on the trend. But the obsession with protein may have started

Key Points Eli Lilly struck a deal with President Donald Trump, lowering the prices of its blockbuster weight loss drugs. In return, Lilly gains exemption

Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said that the company needs to “broaden the portfolio,” as

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer mentioned the stock during the episode and commented:

Photo Illustration by Thomas Levinson/The Daily Beast/Getty He spoke about people being forced to flee “South Africa” due to communism, when he meant to say

Medicine is strongly biased towards adopting biochemical models of disease as this facilitates costly therapeutics being developed for each disease and hence sustains the medical

Post Content

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer, valuing the startup at up

Post Content

Chronic kidney disease (CKD) poses a major global health burden and is one of the most common complications of type 2 diabetes (T2D). Drug trials

President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and

Post Content

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has built a business model centered on personalized, subscription-based care that prioritizes convenience,

Science Advances, Volume 11, Issue 45, November 2025.

  Interview transcript: Terry Gerton: Open Season kicks off today. People might have been a little distracted by all the other things that are happening in

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and

On its third-quarter conference call held on Nov. 4, Pfizer PFE shed light on the two topics for which it has been in the news